Skip to main content

Table 1 Human samples

From: The apolipoprotein receptor LRP3 compromises APP levels

  Age (y) Gender PM (h) SP ApoE
MA NFT
 0 46 f 9.5 0 ɛ2/ɛ3
46 m 15 ɛ3/ɛ4
47 m 5 ɛ3/ɛ3
49 m 7.5 ɛ3/ɛ3
50 m 17 ɛ3/ɛ3
52 m 5 ɛ3/ɛ3
52 f 6 ɛ4/ɛ4
53 m 7.5 ɛ3/ɛ3
56 m 4 ɛ2/ɛ3
59 m 6,5 ɛ3/ɛ3
60 f 11.5 ɛ3/ɛ3
AD NFT
 Braak I 53 m 6.25 A ɛ3/ɛ4
64 m 8.5 0 ɛ3/ɛ3
67 m 14.5 0 ɛ3/ɛ3
68 m 11 0 ɛ2/ɛ3
 Braak II 57 m 4.5 0 ɛ3/ɛ4
60 f 9.5 A ɛ3/ɛ3
65 m 16.5 0 ɛ3/ɛ3
67 m 7.25 0 ɛ3/ɛ4
69 m 3.5 A ɛ3/ɛ4
72 m 6.25 A ɛ3/ɛ4
74 m 5.5 A ɛ2/ɛ3
78 m 16 0 ɛ3/ɛ3
78 m 10.75 B ɛ3/ɛ4
86 m 5.5 A ɛ2/ɛ3
 Braak III 68 f 4.5 A ɛ3/ɛ3
71 m 7.5 0 ɛ2/ɛ3
73 m 4 0 ɛ3/ɛ3
76 f 4 B ɛ3/ɛ3
77 m 13.5 C ɛ3/ɛ4
77 m 5.5 A ɛ3/ɛ3
79 f 3.5 B ɛ3/ɛ3
82 f 5 A ɛ3/ɛ3
90 f 4 B ɛ3/ɛ3
 Braak IV 79 m 5 A ɛ4/ɛ4
81 f 5 C ɛ3/ɛ3
85 m 14 B ɛ3/ɛ4
89 m 3.5 B ɛ3/ɛ4
99 f 5 B ɛ3/ɛ3
 Braak V 72 m 2.75 C ɛ3/ɛ4
73 m 4.5 B ɛ3/ɛ4
74 f 9 A ɛ3/ɛ4
75 m 11.5 B ɛ3/ɛ4
77 m 16 C ɛ3/ɛ3
78 m 17 0 ɛ3/ɛ3
81 f 5.5 C ɛ3/ɛ4
87 m 7 C ɛ3/ɛ3
93 m 3 C ɛ3/ɛ3
 Braak VI 56 f 7 C ɛ3/ɛ3
67 f 8 C ɛ3/ɛ4
86 f 20.5 C ɛ3/ɛ3
  1. Middle-aged (MA) cases and cases with AD-related pathology (AD). Subjects were categorized according to the Braak stage of neurofibrillary tangle (NFT I–VI) and senile plaque staging (0–C) [18, 19]. Age (y years), gender (m male, f female), post-mortem (PM, h hours), SP senile plaques, APOE (APOE alleles, ɛ2, ɛ3, and ɛ4)